Cluster of Acute Toxicity from Ingestion of Synthetic Cannabinoid-Laced Brownies

Journal of Medical Toxicology

Volumn 11, Issue 4, 2015, Pages 426-429

  Obafemi, Adebisi I ^a   Kleinschmidt, Kurt ^a   Goto, Collin ^a   Fout, Drew ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Texas Department of Public Safety   (United States)

Author keywords

Acute toxicity; Cannabis; Novel psychoactive substance; Synthetic cannabinoid receptor agonists; Tachycardia

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST;

ACUTE TOXICITY; ADULT; ARTICLE; CANNABIS USE; CLINICAL ARTICLE; ELECTROCARDIOGRAPHY; FEMALE; HUMAN; MALE; MASS FRAGMENTOGRAPHY; MIDDLE AGED;

ADULT; CANNABINOID RECEPTOR AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84948382424     PISSN: 15569039     EISSN: 19376995     Source Type: Journal    
DOI: 10.1007/s13181-015-0482-z     Document Type: Article

References (26)

1. Brent LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev. 2014;46(1):72–85.
2. Sobolevsky T, Prosolov I, Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post administration urine. Forensic Sci Int. 2010;200:141–7.
3. Spaderma M, Addy PH, D’Souza DC. Spicing thing up: synthetic cannabinoids. Psychopharmacology (Berl). 2013;228(4):525–40.
4. Barrat MJ, Cakic V, Lenton S. Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev. 2013;32(2):141–6.
5. McQuade D, Hudson S, Dargan PI, Wood DM. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol. 2013;69:373–6.
6. Uchiyama N, Kikura-Hanjiri R, Ogata J, Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int. 2010;198(1–3):31–8.
7. European Monitoring Center for Drugs and Drug Addiction E. Thematic paper. Understanding the “Spice” phenomenon. Office for official Publications, Lisbon. 2009. http://www.emcdda.europa.eu/publications.
8. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoid: epidemiology pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144(v):12–41.
9. Gundeson EW, Haughey HM, Ait Daoud N, Joshi AS, Hart CL. A survey of synthetic cannabinoid consumption current cannabis users. Subst Abus. 2014;35(2):184–9.
10. Food and Drug Administration Safety and Innovation Act. United States. 2012. http://www.fda.gov/regulatoryInformation/legislation/federalFoodDrugandCosmeticAct.
11. Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis. 2011;30(4):351–8.
12. Musselman ME, Hampton JP. “Not for human consumption”: a review of emerging designer drugs. Pharmacotherapy. 2014;34(7):745–57.
13. Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana reported to poison centers. Hum Exp Toxicol. 2012;31(10):1006–11.
14. Monte A, Bronstein A, Heard K, Iwanicki J. An outbreak of exposure to a novel synthetic cannabinoid. NEJM. 2013;37:389–90.
15. Mir A, Obafemi A, Young A, Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128(6):e1622–7.
16. Young AC, Schwarz E, Medina G, Obafemi A, Feng SY, Kane C, et al. Cardiotoxicity associated with the synthetic cannabinoid, K9 with laboratory confirmation. Am J Emerg Med. 2012;30(7):1320.
17. Cone EJ, Johnson RE, Paul BD, Mell LD, Mitchell J. Marijuana-laced brownies: behavioral effects, physiologic effects, and urinalysis in human following ingestion. J Anal Toxicol. 1988;12(4):169–75.
18. Centers for Disease control and Prevention (CDC). Inadvertent ingestion of marijuana—Los Angeles, California, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(34):947–50.
19. Heath TS, Burroughs Z, Thompson AJ, Tecklenburg FW. Acute intoxication caused by a synthetic cannabinoid in two adolescents. J Pediatr Pharmacol Ther. 2012;17(2):177–81.
20. Meijer KA, Russo RR, Adhvaryu DV. Smoking synthetic marijuana leads to self- mutilation requiring bilateral amputations. Orthopedics. 2014;37(4):e391–4.
21. Aoun EG, Chritopher PP, Ingraham JW. Emerging drugs of abuse: clinical and legal considerations. R I Med J. 2013;96(6):41–5.
22. Drug Enforcement Administration DJ. Schedules of controlled substances: temporary placement of four synthetic cannabinoids into schedule 1. Fed Regist. 2014;79:1776–80.
23. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. ‘Spice’ and other herbal blend: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44(5):832–7.
24. Hu X, Primack BA, Barnett TE, Cook RL. College students and use of K2: an emerging drug of abuse in young persons. Subst Abuse Treat Prev Policy. 2011;5:16.
25. Heishman SJ, Huetis MA, Henningfield JE. Acute and residual effect of marijuana: profiles of plasma THC levels, physiological, subjective and performance measures. Pharmacol Biochem Behav. 1990;37:561–7.
26. Dewane WA, Breuer A, Sheskin T, Jarbe TU, Eisen MS, Mechoulam R. A novel probe for the cannabinoid receptor. J Med Chem. 1992;35(11):2065–9.